These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22422099)

  • 1. Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas.
    Yamamoto Y; Maeda Y; Kawai N; Kudomi N; Aga F; Ono Y; Nishiyama Y
    Nucl Med Commun; 2012 Jun; 33(6):621-5. PubMed ID: 22422099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
    Kawai N; Lin W; Cao WD; Ogawa D; Miyake K; Haba R; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1870-8. PubMed ID: 24781871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
    Bekaert L; Valable S; Lechapt-Zalcman E; Ponte K; Collet S; Constans JM; Levallet G; Bordji K; Petit E; Branger P; Emery E; Manrique A; Barré L; Bernaudin M; Guillamo JS
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1383-1392. PubMed ID: 28315948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
    Hirata K; Terasaka S; Shiga T; Hattori N; Magota K; Kobayashi H; Yamaguchi S; Houkin K; Tanaka S; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):760-70. PubMed ID: 22307533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
    Cher LM; Murone C; Lawrentschuk N; Ramdave S; Papenfuss A; Hannah A; O'Keefe GJ; Sachinidis JI; Berlangieri SU; Fabinyi G; Scott AM
    J Nucl Med; 2006 Mar; 47(3):410-8. PubMed ID: 16513609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
    Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
    Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
    Wei Y; Zhao W; Huang Y; Yu Q; Zhu S; Wang S; Zhao S; Hu X; Yu J; Yuan S
    PLoS One; 2016; 11(6):e0157606. PubMed ID: 27322586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
    Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
    Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
    Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
    PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
    Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
    Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
    J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between hypoxic area in primary brain tumors and WHO grade: differentiation from malignancy using 18F-fluoromisonidazole positron emission tomography.
    Kanoto M; Kirii K; Hiraka T; Toyoguchi Y; Sugai Y; Matsuda K; Sakurada K; Sonoda Y; Hatazawa J; Hosoya T
    Acta Radiol; 2018 Feb; 59(2):229-235. PubMed ID: 28534419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
    Kawai N; Maeda Y; Kudomi N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):441-50. PubMed ID: 21072512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
    Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
    J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.
    Muzi M; Peterson LM; O'Sullivan JN; Fink JR; Rajendran JG; McLaughlin LJ; Muzi JP; Mankoff DA; Krohn KA
    J Nucl Med; 2015 Aug; 56(8):1223-8. PubMed ID: 26112020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing hypoxia in human glioma: A simultaneous multimodal MRI and PET study.
    Preibisch C; Shi K; Kluge A; Lukas M; Wiestler B; Göttler J; Gempt J; Ringel F; Al Jaberi M; Schlegel J; Meyer B; Zimmer C; Pyka T; Förster S
    NMR Biomed; 2017 Nov; 30(11):. PubMed ID: 28805936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
    Swanson KR; Chakraborty G; Wang CH; Rockne R; Harpold HL; Muzi M; Adamsen TC; Krohn KA; Spence AM
    J Nucl Med; 2009 Jan; 50(1):36-44. PubMed ID: 19091885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.